-
Mashup Score: 0The Next Wave After Immunotherapy in Cancer Drug Development - 6 hour(s) ago
This Viewpoint discusses the history of immunotherapy and the future of targeted therapy to treat cancer.
Source: jamanetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Breast Cancer Outcomes in Transgender and Gender-Diverse Patients in the National Cancer Database - 7 hour(s) ago
This cohort study examines breast cancer outcomes in transgender and gender-diverse patients compared with cisgender patients, including overall survival and sociodemographic characteristics.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Transgender and gender-diverse patients with breast cancer receive less endocrine therapy and have lower 5-year overall survival compared to cisgender patients. https://t.co/rDm1DPA3QL https://t.co/0hRqLnJn5C
-
-
Mashup Score: 0PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer - 12 hour(s) ago
This cohort study evaluates the efficacy of neoadjuvant programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) blockade combined with chemotherapy in enhancing surgical outcomes and pathological responses in patients with stage III non–small cell lung cancer.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Most viewed this week from @JAMAOnc: Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. https://t.co/dsosFnIsya https://t.co/QT72H84nTm
-
-
Mashup Score: 0Tomosynthesis vs Digital Mammography Screening in Women with a Family History of Breast Cancer - 1 day(s) ago
This cohort study compares the performance of digital breast tomosynthesis to conventional digital mammography in screening women with a family history of breast cancer.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Digital breast tomosynthesis improves specificity and reduces recall and advanced cancer rates compared to digital mammography in women with a family history of breast cancer. https://t.co/sFaKIWFLhA https://t.co/J12K6u3muY
-
-
Mashup Score: 101PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer - 2 day(s) ago
This cohort study evaluates the efficacy of neoadjuvant programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) blockade combined with chemotherapy in enhancing surgical outcomes and pathological responses in patients with stage III non–small cell lung cancer.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. https://t.co/Bro2Fxxtzg https://t.co/womJHS8UK9
-
-
Mashup Score: 38Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation Therapy in HPV-Negative Head and Neck Cancer - 3 day(s) ago
This phase 2 nonrandomized clinical trial evaluates the deep response rate and tolerability of neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in nonvirally mediated stage IVa/b head and neck squamous cell carcinoma.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Neoadjuvant nivolumab + chemotherapy followed by response-stratified chemoradiation in stage IVa/b nonvirally mediated head & neck cancer showed favorable survival & less toxic effects. https://t.co/LRbsuJ3oYG https://t.co/izHePaFAm5
-
-
Mashup Score: 26Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation Therapy in HPV-Negative Head and Neck Cancer - 4 day(s) ago
This phase 2 nonrandomized clinical trial evaluates the deep response rate and tolerability of neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in nonvirally mediated stage IVa/b head and neck squamous cell carcinoma.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Neoadjuvant nivolumab + chemotherapy followed by response-stratified chemoradiation in stage IVa/b nonvirally mediated head & neck cancer showed favorable survival & less toxic effects among responders receiving response-adapted chemoradiation. https://t.co/9cQBKoJbP9
-
-
Mashup Score: 70Adjuvant Chemoradiotherapy vs Radiotherapy for Patients With Intermediate-Risk Cervical Cancer - 5 day(s) ago
This cohort study examines the association between adjuvant chemoradiotherapy and overall survival compared with radiotherapy alone in patients with intermediate-risk cervical cancer.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Adding chemotherapy to radiotherapy was not associated with improved overall survival for patients with intermediate-risk cervical cancer. https://t.co/nGzj5EcBBr https://t.co/5wo9uth93N
-
-
Mashup Score: 32
This cohort study examines the harms and benefits of regimens containing immune checkpoint inhibitors in individuals with non–small cell lung cancer.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
Most viewed this week from @JAMAOnc: Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events. https://t.co/KYKx3picR3 https://t.co/OnMt8iSrqb
-
-
Mashup Score: 38Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk - 6 day(s) ago
This cohort study evaluates the time necessary to accurately document a persistent prostate-specific antigen level after radical prostatectomy.
Source: jamanetwork.comCategories: General Medicine NewsTweet-
PSA level should be assessed for at least 3 months after radical prostatectomy to minimize overtreatment, and a higher persistent PSA level was associated with a worse prognosis. https://t.co/INTkAshMdO https://t.co/cPs7oyDJEV
-
Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy. https://t.co/qp8IRdNV6S https://t.co/hJPIeElnuK